Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Generation Bio
The Belgium-headquartered group is pulling the plug on its dry AMD research efforts and investments in cancer venture Oncurious to focus on two early-stage compounds that show promise for diabetic macular edema and other retinal diseases.
A financing round that was significantly oversubscribed by new and existing investors will help advance the Oxford-headquartered biotech's exosome therapeutics into the clinic and expand its technology platform.
Lantern, Avidity, Generation Bio and Vaxcyte launched initial public offerings during the second week of June as biopharma continues to intrigue IPO investors. Also, Blackstone invested $350m in Reata's bardoxolone and Checkmate’s $85m series C led recent VC deals.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
- Chiral Chemistry
- Drug Delivery
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Nanotechnology, Chips, etc.
- Synthesis Technologies, Production Processes
Drug Discovery Tools
- Molecular Diversity
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.